Bristol-Myers Squibb: all 2,184 studies

Page 18 of 22. Open to participants first (162), then studies with results posted, then the rest; newest registration first within each.

• Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedNCT01583283Phase 1
• Korean Post-marketing Surveillance for Orencia®CompletedNCT01583244
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)CompletedNCT01581203Phase 3
• Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)CompletedNCT01575925Phase 1
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)CompletedNCT01573351Phase 3
• A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic SyndromesCompletedNCT01571648Phase 1
• Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01568294Phase 1
• Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedNCT01545947Phase 1
• Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)CompletedNCT01540461Phase 1
• Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With MetforminCompletedNCT01525823Phase 1
• Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical TrialCompletedNCT01525810
• Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected PatientsWithdrawnNCT01525212Phase 1
• Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell DiseaseCompletedNCT01522547Phase 1
• Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral AzacitidineCompletedNCT01519011Phase 1
• Japanese Phase 1 Multiple Ascending Dose StudyCompletedNCT01515202Phase 1
• A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic MelanomaCompletedNCT01511913
• A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsCompletedNCT01497834Phase 3
• Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT01497093Phase 1
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical TrialCompletedNCT01492504
• Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's DiseaseCompletedNCT01492374Phase 1
• Safety Study of IL-21/Ipilimumab Combination in the Treatment of MelanomaCompletedNCT01489059Phase 1
• Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naiveTerminatedNCT01489046Phase 2
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT01478685Phase 1
• Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant StudyCompletedNCT01476943
• A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male SubjectsCompletedNCT01474330Phase 1
• Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy SubjectsCompletedNCT01471717Phase 1/2
• Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy VolunteersCompletedNCT01471704Phase 1/2
• Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant StudyCompletedNCT01471223
• Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT01471210Phase 1
• A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus ErythematosusTerminatedNCT01466725Phase 2
• Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's DiseaseCompletedNCT01466374Phase 2
• Korean Post-marketing Surveillance for Sprycel®CompletedNCT01464047
• Phase 1 Biomarker Study of Anti-PDL-1 in Advanced MelanomaWithdrawnNCT01455103Phase 1
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedNCT01455090Phase 2
• Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163CompletedNCT01454115Phase 1
• Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
• Comparative Tolerability of Protease InhibitorsCompletedNCT01450618
• Korean Post-marketing Surveillance for Reyataz®CompletedNCT01450605
• Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis CWithdrawnNCT01447394Phase 3
• Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve SubjectsCompletedNCT01445795Phase 1/2
• Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or RibavirinTerminatedNCT01425970Phase 2
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
• Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2
• Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2
• Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid TumorsCompletedNCT01413906Phase 1
• Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid ArthritisCompletedNCT01404585Phase 2
• Japanese Phase 1 Multiple Ascending Dose (MAD) StudyCompletedNCT01396252Phase 1
• Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)CompletedNCT01394666
• Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in EuropeCompletedNCT01389310
• Evaluating Nulojix (Belatacept) Long-Term Safety in TransplantCompletedNCT01386359
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major DepressionCompletedNCT01369095Phase 2
• Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT01363817Phase 1
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major DepressionTerminatedNCT01361555Phase 2
• Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT01359657Phase 1
• An Observational Registry of Abatacept in Patients With Juvenile Idiopathic ArthritisActive, not recruitingNCT01357668
• Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation BurdenCompletedNCT01356914Phase 2
• Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B PatientsCompletedNCT01356901
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
• MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National RegistryCompletedNCT01347944
• A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) TrialsCompletedNCT01337479
• Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple MyelomaCompletedNCT01323751Phase 1/2
• Diabetic Peripheral Neuropathic Pain (DPNP)CompletedNCT01314222Phase 2
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major DepressionCompletedNCT01309945Phase 2
• Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedNCT01309932Phase 2
• Crossover Post-herpetic Neuralgia (PHN)CompletedNCT01305538Phase 2
• Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative ColitisCompletedNCT01294410Phase 2
• Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT01292655Phase 1
• Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 DiabetesCompletedNCT01290575Phase 1
• Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve SubjectsCompletedNCT01250366Phase 1
• Safety Study of Abatacept to Treat Rheumatoid ArthritisCompletedNCT01247766
• Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaCompletedNCT01245556Phase 1
• Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world SettingCompletedNCT01244750
• Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)CompletedNCT01240980Phase 1
• Study on Long Term Outcomes of Atazanavir in Antiretroviral-naïve Human Immunodeficiency Virus (HIV) Patients in Real Life SettingCompletedNCT01236235
• Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of AbataceptWithdrawnNCT01221636Phase 1
• Effect of BMS-914392 on Pharmacokinetics of MetoprololCompletedNCT01211821Phase 1
• Effect of Diltiazem on Pharmacokinetics of BMS-914392CompletedNCT01211808Phase 1
• Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCompletedNCT01204762Phase 2
• A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT01203943Phase 2
• Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous CatheterTerminatedNCT01195727Phase 1
• Ph IIA Study (SOC +/- NS5B)CompletedNCT01193361Phase 2
• Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure SurveyCompletedNCT01188278
• A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell LymphomaCompletedNCT01169298Phase 1
• Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseCompletedNCT01167244Phase 2
• Observational Real-world Evaluation of Cost of Infections of Rheumatoid Arthritis (RA) Patients on BiologicsCompletedNCT01166620
• A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or LymphomasTerminatedNCT01163071Phase 1
• A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy SubjectsCompletedNCT01159808Phase 1
• Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB)CompletedNCT01155427
• Experimental Study to Validate the Modified Glucose Disposal TestCompletedNCT01152372Phase 1
• Japanese Phase 1 Study of BMS-844203 (CT322)WithdrawnNCT01146171Phase 1
• A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype IWithdrawnNCT01142700Phase 2
• Dose Escalation With Remicade® and Orencia®CompletedNCT01141413
• Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis PatientsCompletedNCT01137851
• Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic AgentsCompletedNCT01137838
• Predictors of Adherence to OrenciaCompletedNCT01136707
• Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)CompletedNCT01136694
• Safety and Pharmacology Study of BMS-866949TerminatedNCT01124344Phase 1
• First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCompletedNCT01120457Phase 1
• Safety Study of BMS-823778 in Subjects With HypercholesterolemiaCompletedNCT01112423Phase 2

← Bristol-Myers Squibb overview and focus areas